Updated time: 2021-08-19 16:52:03
Using TIFA dominant-negative fragments inhibits NF-kB activation and meets the large unmet medical needs.
This invention describes a method to inhibit “NF-kB activation by expression of dominant negative fragments of TIFA as an approach in disease treatment”. Similar approaches using dominant negative IKKb(NEMO-binding domain, NBD) and p105-based NF-kB super repressors (p105[sr], partially deleted full-length NF-kB p105) have been designed and patented (United States Patent: 6,864,355 and 8,722,613, respectively), however, both patents provided inhibitory effects that were validated in test tube without showing a therapeutic implication in vivo. The method we designed copes with the NF-kB repressor activity by TIFA DNs as a “therapeutic approach to treat with inflammation-associated diseases” that include, but are not limited to, acute myeloid leukemia (AML).
11A-1060119
US 10322165 B2、TW I734814
Diseases with related pro-inflammatory or inflammatory responses, including those with unmet medical needs such as acute myeloid leukemia (AML), various cancer types, cardio vascular diseases, etc.
Ming-Daw Tsai, Tong-You Wade Wei, Pei-Yu Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Using the dominant-negative fragments of TIFA as a method to inhibit NF-kB activation in disease treatment